Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.
Hosted on MSN20h
Dexcom Stock Makes A Recovery After Its Fourth-Quarter FumbleDexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.
A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...
Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...
Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.5% in the 4th quarter, ...
Latin America continuous glucose monitoring device market is estimated to be valued at US$ 219.3 mn in 2025 and is expected to exhibit a CAGR of 15.8% by 2032 BURLINGAME, CA, UNITED STATES ...
An Apple Watch, which integrates easily into the Dexcom CGM ecosystem ... Until then, if you need a primer on continuous glucose monitoring, we’re happy to oblige.
In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with ...
BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback